(Q35023348)

5 August 2017

Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects (English)

1 reference

5 August 2017

1 reference

1 reference

Edwin DeJesus

1

1 reference

5 August 2017

Peter J Piliero

2

1 reference

5 August 2017

Kim Summers

3

1 reference

5 August 2017

Mary Beth Wire

4

1 reference

5 August 2017

Daniel S Stein

5

1 reference

5 August 2017

Amanda Masterman

6

1 reference

5 August 2017

Yu Lou

7

1 reference

5 August 2017

Sherene S Min

8

1 reference

5 August 2017

Mark J Shelton

9

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Antimicrobial Agents and Chemotherapy

5 August 2017

1 reference

5 August 2017

50

1 reference

5 August 2017

9

1 reference

5 August 2017

3157-3159

1 reference

Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

Liver toxicity caused by nevirapine

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1563559

25 October 2018

Identifiers

DOI

10.1128/AAC.00093-06

1 reference

5 August 2017

1 reference

5 August 2017

1 reference